Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

News.

Here you will find information and news about the latest events. In this way, you can stay ‘a heartbeat ahead’
of developments.

Also available as RSS feed for your RSS feed reader.

You can subscribe to our newsletter here:

CARL. Resuscitec awarded with the Lothar Späth Award 2023
11/17/23

Yesterday, Thursday evening, November 16, 2023, Resuscitec, represented by our management Prof. Benk, Mr. Ronde and Dr. Kraft, together with our cooperation partner from the Medical Center – University of Freiburg, represented by Prof. Beyersdorf, received the 1st prize of the Lothar Späth Award 2023 in the Zeiss Planetarium Jena.

Learn more >
Resuscitec selected to be one of the ‘Top 10 MedTech Startups in Europe 2023’
11/09/23

MedTech Outlook Magazine is an international medical technology magazine with over 132,300 subscribers across Europe. Each year, the European edition of the magazine shortlists 10 companies to be part of the ‘Top 10 MedTech Startups in Europe’.

Learn more >
1st Summit
09/22/23

On September 15 and 16, CARL Academy welcomed over 100 European ECPR and CARL experts to the first edition of the CARL Summit in Freiburg, Germany. In many inspiring presentations and discussions, the leading key opinion leaders in the field shared their expertise, recent experiences and tips and tricks for the successful realization of ECPR programs. An important step to shape the future of ECPR.

Learn more >
„Freiburg model” for Life Saving of Resuscitation Patients
05/12/23

Yesterday, Florian Wahl, Chairman of the Committee for Social Affairs, Health and Integration in the State Parliament of Baden-Württemberg (BW), together with an SPD delegation from Freiburg and BW, visited the University Emergency Center of the Medical Center – University of Freiburg and the CARL Academy in the Güterhalle.

Learn more >
Resuscitec GmbH at the ECPR School in Prague
10/25/22

Resuscitec GmbH will be represented at the ECPR School in Prague from 27 to 28 October 2002 with its own booth (no. 5) in the Cubex Center and will also organize a breakfast workshop on October 28. On this occasion, Christoph Benk from the University Medical Center Freiburg will present the CARL System, and Eike Tigges from the Asklepios Klinik St. Georg in Hamburg will report on the first CARL deployments in the clinic.

Learn more >
Dr. Thomas Kraft reinforces the management of Resuscitec GmbH
10/20/22

Dr. Thomas Kraft joins the management team of Resuscitec GmbH, which currently consists of Prof. Christoph Benk (CTO) and Jörg Ronde (CFO), effective October 1, 2022. As CEO, the 47-year-old will assume the role of Chairman of the Management Board as well as functional responsibility for the Sales, Marketing and Medical Alliance departments.

Learn more >
EACTS Annual Meeting 2022
10/19/22

More than 3.500 Heart and Thorax Physicians from all over the world attended the 36th Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in Milan from October 5 to 8, 2022. Resuscitec GmbH presented itself for the first time with its own booth in the Milano Convention Center (MiCo) and introduced the CARL Therapy as well as the CARL System to many interested parties from Europe, Asia and America.

Learn more >
First digital trade fair appearance of CARL.
02/23/22

Resuscitec GmbH successfully participated in the digital 51st Annual Meeting of the German Society for Thoracic, Cardiac and Vascular Surgery (DGTHG) and the 54th Annual Meeting of the German Society for Pediatric Cardiology and Congenital Heart Defects (DGPK) from February 18 to 22, 2022.

Learn more >